AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States.
It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture.
In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets.
Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries.
The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors.
It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific.
The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003.
Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
Country | United States |
IPO Date | Apr 11, 2014 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 1,940 |
CEO | Jack Clifford Bendheim |
Contact Details
Address: Glenpointe Centre East Teaneck, New Jersey United States | |
Website | https://www.pahc.com |
Stock Details
Ticker Symbol | PAHC |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001069899 |
CUSIP Number | 71742Q106 |
ISIN Number | US71742Q1067 |
Employer ID | 13-1840497 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jack Clifford Bendheim | Chairman, President & Chief Executive Officer |
Glenn C. David | Chief Financial Officer |
Larry L. Miller | Chief Operating Officer |
Daniel M. Bendheim J.D. | Executive Vice President of Corporate Strategy & Director |
Jonathan Bendheim | President of MACIE Region, GM of Israel Operations & Director |
Judith A. Weinstein | Senior Vice President, General Counsel & Corporate Secretary |
Lisa A. Escudero | Senior Vice President of Human Resources |
Ramon Fuenmayor | President South America Region |
Rob Aukerman | Advisor |
Samson Li | President of Asia Pacific Region |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 07, 2025 | 8-K/A | [Amend] Current Report |
Nov 15, 2024 | SC 13D/A | [Amend] Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | 8-K | Current Report |
Nov 06, 2024 | 8-K | Current Report |
Nov 06, 2024 | 10-Q | Quarterly Report |
Nov 05, 2024 | 8-K | Current Report |
Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 31, 2024 | 8-K | Current Report |